

**Press Release**

*For Immediate Release*

**Gleneagles Hospital Hong Kong Signs Collaboration Agreement with HKSTP  
to Drive Cutting-Edge Innovation and Advance Patient Care**

- HKSTP signed a collaboration agreement with Gleneagles Hospital Hong Kong to advance patient care through the co-creation of innovative products and services for clinical use.
- Park company Codex Genetics' AI-powered treatment matching platform will allow Gleneagles to expand patient access to treatment options.
- HKSTP MedTech Co-Create Programme offers technology matching opportunities to accelerate the development of clinical use cases and encourage wider adoption.

**(Hong Kong, 12 June 2023)** – Hong Kong Science and Technology Parks Corporation (HKSTP), today announced its partnership with Gleneagles Hospital Hong Kong (Gleneagles) to advance patient care through the co-creation of innovative products and services for clinical use.

The strategic partnership has been formed under the HKSTP MedTech Co-Create Programme (MTCC), an open innovation platform to foster collaboration and integrate technological innovations into patient care pathways. The partnership will see Gleneagles combine its deep medical expertise and clinical research capability with HKSTP's biomedical technology ecosystem and expert network, to translate research into commercially viable, high-impact innovation.

Mr Albert Wong, CEO of HKSTP, said, "The HKSTP ecosystem has a track record of nurturing and producing high quality health and biotech companies who are pushing the boundaries in their field. With more than 210 biomedical Park companies and incubatees and over 1,200 researchers from 12 countries, today HKSTP has a strong portfolio of translational research and development. By matching these with Gleneagles, one of the most innovative and progressive private hospitals in Asia, we can open new opportunities for co-creation that can rapidly translate research into clinical and commercial successes."

During an inaugural meeting under the MTCC programme between HKSTP and Gleneagles in early 2022, precision oncology was identified as an initial area of interest. Matching sessions were arranged for Gleneagles with Park companies in this area covering artificial intelligence (AI) and laboratory testing. This resulted in a successful collaboration with Codex Genetics, a homegrown company at Science Park specialising in deep patient profiling to guide disease management. The collaboration will see the two parties expand patient access to the latest personalised treatment options through an AI-powered treatment matching platform.

Dr Grace Lau, Head of Institute for Translational Research, HKSTP, said, "This partnership further expedites the translation of biomedical technologies to benefit the public. Throughout the technology translation journey from ideation to development, commercialisation and adoption, the MTCC Programme represents one of HKSTP's initiatives to bridge "the last mile" in technology implementation and adoption. With MTCC, we connect technology adopters including leading medical institutes like Gleneagles with strong tech

providers to co-create clinical use cases. We have in our ecosystem a portfolio of mature technologies that are ready for clinical integration, including AI and precision oncology solutions provided by Codex Genetics. MTCC provides an open platform for the community including healthcare professionals to discover and explore these technologies, and to co-create with our partner companies, with a shared vision to bring forward integrated, patient-centric care.”

Dr Kenneth Tsang, CEO of Gleneagles Hospital Hong Kong, added, “Gleneagles has been striving to continuously transform and improve patient care through leveraging healthcare technological innovations. We are pleased to collaborate with HKSTP, which is providing us with access to one of the richest health and biotechnology innovation ecosystems in Asia. We look forward to deepening our partnership with HKSTP to contribute to the development of innovative technologies, and ultimately translate them into impactful healthcare solutions for patients.”

Through the collaboration, Gleneagles and HKSTP will continue to explore and expand its areas of collaboration across more areas including managing health data.



**Photo 1:** Mr Albert Wong, CEO of HKSTP (second from left) and Dr Kenneth Tsang, CEO of Gleneagles Hospital Hong Kong (second from right) signed the agreement for a collaboration framework on advancing patient care through the co-creation of innovation products and services for clinical use. Dr Grace Lau, Head of Institute for Translational Research, HKSTP (first from left) and Mr Paul Lau, CFO of Gleneagles Hospital Hong Kong (first from right) also attended the signing ceremony.



**Photo 2:** From left to right - Dr Aldrin Yim, Founder and CEO, Codex Genetics; Dr Grace Lau, Head of Institute for Translational Research, HKSTP; Dr Kenneth Tsang, CEO of Gleneagles Hospital Hong Kong; Dr Allen Yu, Founder and CTO, Codex Genetics.

###

### **About Hong Kong Science and Technology Parks Corporation**

Hong Kong Science and Technology Parks Corporation (HKSTP) has for over 20 years committed to building up Hong Kong as an international innovation and technology hub to propel success for local and global pioneers today and tomorrow. HKSTP has established a thriving I&T ecosystem that supported 14 unicorns and Hong Kong's leading R&D hub with over 13,000 research professionals and over 1,400 technology companies focused on healthtech, AI and robotics, fintech and smart city technologies.

Established in 2001, we attract and nurture talent, accelerate and commercialise innovation and technology for entrepreneurs on their journey of growth in Hong Kong, to the Greater Bay Area, Asia and beyond. Our growing innovation ecosystem is built around our key locations of Hong Kong Science Park in Shatin, InnoCentre in Kowloon Tong and three modern INNOPARKs in Tai Po, Tseung Kwan O and Yuen Long. The three INNOPARKs are realising a vision of new industrialisation for Hong Kong. The goal is sectors like advanced manufacturing, electronics and biotechnology are being reimaged for a new generation of industry.

Through our infrastructure, services, expertise and network of partnerships, HKSTP will help establish innovation and technology as a pillar of growth for Hong Kong, while reinforcing Hong Kong's international I&T hub status as a launchpad for global growth at the heart of the GBA innovation powerhouse.

More information about HKSTP is available at [www.hkstp.org](http://www.hkstp.org).

### **About HKSTP MedTech Co-Crete Programme (MTCC)**

The Programme is an open innovation platform to foster collaborations and integrate technological innovations into patient care pathway. The Programme primarily aims to bring forwards Healthcare Integration which is a collaborative approach across multi-disciplines throughout the entire patient journey to optimize patient outcomes and save costs. The Programme features a medical communication platform to showcase Science Park's healthcare innovations to the wide medical community, e.g., in partnership with Hong Kong Medical Association. Advisory services and funding support of up to HK\$ 2 million per project are provided to stimulate co-creations between Park companies to develop impactful products. As our partners are key to the co-creation and adoption of these innovations – MedTech Co-Crete is building on partnerships with hospital networks, MNC Pharmas, applied research institutes, and other key stakeholders.

### **About Gleneagles Hospital Hong Kong**

Located in Wong Chuk Hang in Hong Kong Island South, Gleneagles Hospital Hong Kong (Gleneagles) is a multi-specialty private hospital, providing 500 beds, cutting-edge medical technologies and a comprehensive range of clinical services spanning more than 35 specialties and subspecialties. As Hong Kong's top-notch private teaching hospital, Gleneagles also contributes to the training and development of healthcare professionals and advancement of clinical research. Gleneagles is a joint venture between IHH Healthcare and NWS Holdings Limited, with The University of Hong Kong as its exclusive clinical partner.

Gleneagles is a member of IHH Healthcare, one of the largest healthcare groups in the world. IHH Healthcare is devoted to providing comprehensive medical services with its dedicated team, influential group and scale, as well as commitment to quality and safety, and hopes to become the most trusted medical service organization in the world. IHH Healthcare upholds the belief: to touch lives and transform care. More information on Gleneagles Hospital Hong Kong can be found at <https://gleneagles.hk>.

#### **Media Contact:**

##### **Hong Kong Science and Technology Parks Corporation**

Julia Cheung

Tel: 2629 6891

Email: [julia.cheung@hkstp.org](mailto:julia.cheung@hkstp.org)

##### **Gleneagles Hospital Hong Kong**

Tracy Chow

Tel: 3153 9330

Email: [tracy.chow@gleneagles.hk](mailto:tracy.chow@gleneagles.hk)

##### **Edelman Public Relations**

Sonia Leung

Tel: +852 2837 4775

Email: [Sonia.Leung@edelman.com/](mailto:Sonia.Leung@edelman.com/)

[Edelmanhkstppr@edelman.com](mailto:Edelmanhkstppr@edelman.com)